Discover tapinarof cream 1%, a novel nonsteroidal aryl hydrocarbon receptor agonist, that has emerged as a promising solution ...

The following is a summary of “Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis ...

Discover a recent randomised clinical trial that evaluated the efficacy of a new monoclonal antibody to treat plaque ...

If you’re knowingly (and frustratingly) nodding your head, then you’re likely familiar with the autoimmune disease psoriasis, ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

It wasn’t until two years after her symptoms began that she finally found a dermatologist who identified her “itchy spots” as evidence of plaque psoriasis, a chronic autoimmune disorder that ...

Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by silvery-white scales. They typically have well-defined edges and may itch.

That’s because certain genes play a role. Psoriasis is a skin disease that affects about 8 million Americans. It comes in several forms. Plaque psoriasis is the most common. Plaque psoriasis ...

Findings showed 64.7% of icotrokinra-treated patients achieved IGA scores 0/1 and 49.6% achieved PASI 90 compared with 8.3% and 4.4% of those on placebo, respectively. Topline results were ...

Guttate psoriasis may represent the initial stage of chronic plaque-type psoriasis. On resolution, post-inflammatory hypo or hyperpigmentation may result. There is no scarring. Patients should be ...

Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra (JNJ-2113) for treating moderate to severe plaque psoriasis in patients aged ...

Plaque psoriasis brings extra challenges when you’re a person of color. These tips can help you partner with your doctor for the best care possible. See More on Psoriasis From WebMD ...